Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
Company profile
Website
CEO
Heather M. Bresch
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Mylan N.V., New Moon B.V.
SEC CIK
Corporate docs
Subsidiaries
Agila Australasia Pty Ltd • Alphapharm Pty. Ltd. • Mylan Australia Holding Pty Ltd • Mylan Australia Pty Limited • Mylan Health Pty. Ltd. • Arcana Arzneimittel GmbH • Meda Pharma GmbH • Mylan Österreich GmbH • Meda Pharma S.A. • Mylan BVBA ...
Latest filings (excl ownership)
S-3ASR
Automatic shelf registration
6 May 22
EFFECT
Notice of effectiveness
29 Sep 21
424B3
Prospectus supplement
28 Sep 21
UPLOAD
Letter from SEC
17 Sep 21
S-4
Registration of securities issued in business combination transactions
10 Sep 21
15-15D
Suspension of duty to report
27 Nov 20
8-K
Entry into a Material Definitive Agreement
19 Nov 20
25-NSE
Exchange delisting
16 Nov 20
10-Q
2020 Q3
Quarterly report
6 Nov 20
8-K
Results of Operations and Financial Condition
6 Nov 20
Transcripts
Earnings call transcript
2020 Q2
7 Aug 20
Earnings call transcript
2020 Q1
11 May 20
Earnings call transcript
2019 Q4
27 Feb 20
Earnings call transcript
2019 Q3
5 Nov 19
Earnings call transcript
2019 Q1
7 May 19
Earnings call transcript
2018 Q4
27 Feb 19
Earnings call transcript
2018 Q3
5 Nov 18
Earnings call transcript
2018 Q2
8 Aug 18
Earnings call transcript
2018 Q1
9 May 18
Earnings call transcript
2017 Q4
28 Feb 18
Latest ownership filings
Financial summary
Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | Dec 18 | Dec 17 | Dec 16 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|